Clinical Trial Update: Single Dose Study of SHR4640 in Healthy Subjects [Phase 1]

View source ↗

Summary

This report notes the completion of a Phase 1 single-dose study of SHR4640 in healthy subjects to assess safety and pharmacokinetics for gout and hyperuricemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• SHR4640

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Gout; Hyperuricemia | Phase 1 | Status: COMPLETED